AML
Haematology · 2017–2024
12decisions
8medicines
8carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| liposomal daunorubicin and cytarabine Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in… | Apr 2024 | Recommended with restriction | no section in document |
| daunorubicin with cytarabine (liposomal) Treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes… | Jul 2023 | Not recommended | input received |
| daunorubicin with cytarabine Treatment of newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) in adults. | Nov 2023 | Recommended | input received |
| azacitidine Maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieve complete remission (CR) or complete remission with incomplete blood count… | Jul 2022 | Recommended with restriction | 2 individuals Leukaemia Foundation · Eastern Cooperative Oncology Group |
| gilteritinib Treatment of patients with relapsed or refractory acute myeloid leukaemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation. | Mar 2022 | Recommended with restriction | input received |
| venetoclax Treatment of newly diagnosed acute myeloid leukaemia (AML) in adults ineligible for standard intensive remission induction chemotherapy, in combination with… | Jul 2021 | Recommended with restriction | 1 individuals |
| gemtuzumab ozogamicin Previously untreated, de novo CD33-positive acute myeloid leukaemia (except acute promyelocytic leukaemia) in patients without confirmed unfavourable… | Mar 2021 | Not recommended | input received Leukaemia Foundation · Rare Cancers Australia |
| venetoclax Treatment of patients with newly diagnosed acute myeloid leukaemia (AML), ineligible for standard intensive remission induction chemotherapy, given in… | Mar 2021 | Recommended with restriction | input received Leukaemia Foundation · Rare Cancers Australia |
| gemtuzumab ozogamicin Treatment of previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia, with… | Nov 2021 | Recommended with restriction | unclear |
| gilteritinib Relapsed or refractory acute myeloid leukaemia with FMS-like tyrosine kinase 3 (FLT3) mutation. | Nov 2021 | Recommended with restriction | input received Leukaemia Foundation · Eastern Cooperative Oncology Group |
| midostaurin Treatment of FLT3 mutation positive acute myeloid leukaemia (AML) in newly diagnosed patients eligible for standard intensive remission induction chemotherapy. | Jul 2018 | Recommended with restriction | none received |
| midostaurin Treatment of FMS-like tyrosine kinase-3 (FLT3) mutation positive acute myeloid leukaemia (AML) in newly diagnosed patients eligible for standard intensive… | Nov 2017 | Not recommended | none received |
Who spoke
Leukaemia Foundation · Eastern Cooperative Oncology Group · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 12 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.